Related Experiment Video
Updated: Jul 2, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual
Xubo Gong1, Xin He2, Lin Wang1
1Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China.
Abstract:
Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venetoclax (VEN) with hypomethylating agents has been established as the standard treatment for elderly or medically unfit AML patients unable to undergo intensive chemotherapy. Despite this, the availability of novel VEN-based therapies specifically tailored for those with R/R AML remains scarce. Here, we provide a comprehensive overview of the latest data presented at the 65th American Society of Hematology Annual Meeting, shedding light on the progress and efficacy of VEN-based therapies for R/R AML.
Insights
Relapsed or refractory acute myeloid leukemia (AML) has limited treatment options. New venetoclax-based therapies show promise for R/R AML patients, offering improved efficacy and hope.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Relapsed or refractory acute myeloid leukemia (R/R AML) presents significant treatment challenges with poor prognosis.
- Current standard of care for unfit AML patients involves venetoclax (VEN) combined with hypomethylating agents.
- Limited novel VEN-based treatment options exist specifically for R/R AML.
Discussion:
- The 65th American Society of Hematology (ASH) Annual Meeting highlighted emerging VEN-based therapies for R/R AML.
- Data presented focused on the efficacy and safety of these novel treatment strategies.
- Understanding these advancements is crucial for optimizing R/R AML patient care.
Key Insights:
- Venetoclax-based combinations demonstrate encouraging efficacy in R/R AML.
- Ongoing research is expanding the therapeutic landscape for this challenging patient population.
- Early clinical data suggests potential for improved outcomes with novel VEN regimens.
Outlook:
- Further clinical trials are necessary to validate the long-term efficacy and safety of these VEN-based therapies.
- Personalized treatment approaches may emerge based on R/R AML patient characteristics.
- These advancements represent a significant step forward in managing R/R AML.
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Preclinical Development: Overview